131 related articles for article (PubMed ID: 3770037)
1. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
Riccardi A; Merlini G; Montecucco C; Danova M; Ucci G; Cassano E; Ascari E
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):787-91. PubMed ID: 3770037
[TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.
Riccardi A; Ucci G; Luoni R; Brugnatelli S; Mora O; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Alberio F
Br J Cancer; 1994 Dec; 70(6):1203-10. PubMed ID: 7981078
[TBL] [Abstract][Full Text] [Related]
3. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma.
Merlini G; Riccardi A; Riccardi PG; Montecucco CM; Pavesi F; Ascari E
Tumori; 1985 Dec; 71(6):581-8. PubMed ID: 4082291
[TBL] [Abstract][Full Text] [Related]
4. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
[TBL] [Abstract][Full Text] [Related]
5. Peptichemio induction therapy in myelomatosis.
Merlini G; Gobbi PG; Riccardi A; Riva G; Sardi C; Perugini S
Cancer Chemother Pharmacol; 1982; 8(1):9-16. PubMed ID: 7094202
[TBL] [Abstract][Full Text] [Related]
6. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
[TBL] [Abstract][Full Text] [Related]
7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
8. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
[TBL] [Abstract][Full Text] [Related]
9. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
[No Abstract] [Full Text] [Related]
10. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
11. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
14. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
[TBL] [Abstract][Full Text] [Related]
15. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
17. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
[TBL] [Abstract][Full Text] [Related]
18. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
19. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]